Epidemiology and natural history of central venous access device use and infusion pump function in the NO16966 trial.

ABSTRACT:

Background

Central venous access devices in fluoropyrimidine therapy are associated with complications; however, reliable data are lacking regarding their natural history, associated complications and infusion pump performance in patients with metastatic colorectal cancer.

Methods

We assessed device placement, use during treatment, associated clinical outcomes and infusion pump performance in the NO16966 trial.

Results

Device replacement was more common with FOLFOX-4 (5-fluorouracil (5-FU)+oxaliplatin) than XELOX (capecitabine+oxaliplatin) (14.1% vs 5.1%). Baseline device-associated events and post-baseline removal-/placement-related events occurred more frequently with FOLFOX-4 than XELOX (11.5% vs 2.4% and 8.5% vs 2.1%). Pump malfunctions, primarily infusion acceler

SUBMITTER: Chu E 

PROVIDER: S-EPMC3960626 | biostudies-literature | 2014 Mar

REPOSITORIES: biostudies-literature